| human | Q5 |
| P496 | ORCID iD | 0000-0003-1192-1465 |
| P69 | educated at | The University of Texas MD Anderson Cancer Center | Q1525831 |
| P735 | given name | Taqi | Q61460298 |
| Taqi | Q61460298 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q40401097 | AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia |
| Q40282557 | Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells |
| Q36770182 | Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia |
| Q40560166 | An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis |
| Q44163463 | Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival |
| Q39554914 | Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor |
| Q52641917 | Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. |
| Q79316212 | Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease |
| Q35766129 | Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). |
| Q47665600 | Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma |
| Q38695362 | Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation |
| Q27853179 | Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib |
| Q40243206 | EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation |
| Q40263124 | Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit |
| Q35995222 | Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome |
| Q34162729 | Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias |
| Q40127047 | Imatinib effect on growth and signal transduction in polycythemia vera |
| Q35575492 | Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status |
| Q35229978 | Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001 |
| Q44429194 | Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome |
| Q43633203 | Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia |
| Q33386057 | Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis |
| Q35229969 | MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells |
| Q37083947 | Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a |
| Q31155471 | Molecular differences between small and large cells in patients with chronic lymphocytic leukemia |
| Q91467070 | Myelofibrosis osteoclasts are clonal and functionally impaired |
| Q33442613 | Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis |
| Q36938773 | Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera |
| Q33387514 | Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis |
| Q37247964 | Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis |
| Q34284684 | Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis |
| Q39717742 | Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor |
| Q34021151 | Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms |
| Q37197964 | Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis |
| Q40114178 | The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation |
| Q36843673 | The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms |
| Q89776924 | Therapy-related myelofibrosis does not appear to exist |
| Q34745101 | WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation |
| Q92668470 | miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2 |
Search more.